文献速递乳腺外科

全国注册研究:不可触及乳腺导管原位癌及浸润性癌定位技术趋势与再手术率

Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer.
PubMed 文献 · Br J Surg · 2021-01-01

该研究基于荷兰全国乳腺癌审计2013–2018年数据,纳入28 370例接受保乳手术前肿瘤定位的不可触及乳腺癌或导管原位癌女性患者,分析定位技术趋势及定位技术与再手术的关联。结果显示放射性粒子定位(RSL)使用率从15.7%升至61.1%,导丝定位(WGL)从75.4%降至31.6%;无论DCIS还是浸润性癌,RSL与WGL相比再手术 odds 均无显著差异。

要点

  • RSL正快速取代WGL成为术前定位技术。
  • 定位技术类型与再手术 odds 无显著关联。
  • DCIS与浸润性癌亚组结果一致。

核心结论

  • RSL正快速取代WGL作为乳腺手术术前定位技术。
  • 大型全国注册研究未发现定位技术类型与再手术 odds 存在关联。

研究设计与样本

  • 全国性注册队列研究,数据来自2013–2018年荷兰全国乳腺癌审计。
  • 纳入28 370例接受保乳手术前肿瘤定位的不可触及乳腺癌或导管原位癌女性患者。

主要发现

  • RSL使用率从15.7%上升至61.1%,WGL从75.4%下降至31.6%。
  • DCIS患者中RSL对比WGL的再手术 odds ratio 为0.96(95%CI 0.89–1.03;P=0.281)。
  • 浸润性乳腺癌患者中RSL对比WGL的再手术 OR 为1.02(95%CI 0.96–1.10;P=0.518)。

临床怎么用

  • 在不可触及乳腺病变保乳手术中,RSL可作为WGL的替代定位技术。
  • 选择定位技术时,再手术风险不应作为区分RSL与WGL的主要依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a transition from wire-guided localization (WGL) of non-palpable breast cancer to other localization techniques. Multiple prospective studies have sought to establish superior clinical outcomes for radioactive-seed localization (RSL), but consistent and congruent evidence is missing. METHODS: In this study, female patients with breast cancer operated with breast-conserving surgery after tumour localization of a non-palpable breast cancer or ductal carcinoma in situ (DCIS) were included. The cohort was identified from the nationwide Netherlands Breast Cancer Audit conducted between 2013 and 2018. Trends in localization techniques were analysed. Univariable and multivariable analyses were performed to assess the association between the localization technique and the probability of a reoperation. RESULTS: A total of 28 370 patients were included in the study cohort. The use of RSL increased from 15.7 to 61.1 per cent during the study years, while WGL decreased from 75.4 to 31.6 per cent. The localization technique used (RSL versus WGL) was not significantly associated with the odds of a reoperation, regardless of whether the lesion was DCIS (odds ratio 0.96 (95 per cent c.i. 0.89 to 1.03; P = 0.281)) or invasive breast cancer (OR 1.02 (95 per cent c.i. 0.96 to 1.10; P = 0.518)). CONCLUSION: RSL is rapidly replacing WGL as the preoperative localization technique in breast surgery. This large nationwide registry study found no association between the type of localization technique and the odds of having a reoperation, thus confirming the results of previous prospective cohort studies.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Schermers B, van Riet YE, Schipper RJ, et al. Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer. Br J Surg. 2021. PMID: 34642736. doi:10.1093/bjs/znab339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。